NNC6019-0001
Phase 2Active 1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Conditions
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Trial Timeline
Feb 20, 2024 → Aug 15, 2028
NCT ID
NCT06260709About NNC6019-0001
NNC6019-0001 is a phase 2 stage product being developed by Novo Nordisk for Transthyretin Amyloid Cardiomyopathy (ATTR CM). The current trial status is active. This product is registered under clinical trial identifier NCT06260709. Target conditions include Transthyretin Amyloid Cardiomyopathy (ATTR CM).
What happened to similar drugs?
3 of 19 similar drugs in Transthyretin Amyloid Cardiomyopathy (ATTR CM) were approved
Approved (3) Terminated (0) Active (16)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06260709 | Phase 2 | Active |
Competing Products
20 competing products in Transthyretin Amyloid Cardiomyopathy (ATTR CM)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Eplontersen Solution for Injection | AstraZeneca | Phase 1 | 29 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 44 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | AstraZeneca | Pre-clinical | 33 |
| Eplontersen | AstraZeneca | Phase 3 | 47 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 44 |
| NNC6019-0001 + Placebo (NNC6019-0001) | Novo Nordisk | Phase 3 | 47 |
| NNC6019-0001 + Placebo (NNC6019-0001) | Novo Nordisk | Phase 2 | 35 |
| Coramitug | Novo Nordisk | Phase 1 | 36 |
| Tafamidis | Pfizer | Pre-clinical | 26 |
| Tafamidis | Pfizer | Pre-clinical | 30 |
| tafamidis meglumine | Pfizer | Approved | 43 |
| Fx-1006A | Pfizer | Phase 2 | 35 |
| Tafamidis | Pfizer | Phase 3 | 40 |
| Tafamidis 61 milligrams | Pfizer | Pre-clinical | 26 |
| Treatment for TTR amyloidosis + Treatment for TTR amyloidosis | Pfizer | Pre-clinical | 26 |
| Vyndaqel | Pfizer | Pre-clinical | 26 |
| tafamidis | Pfizer | Phase 3 | 40 |
| Tafamidis | Pfizer | Approved | 43 |
| Tafamidis | Pfizer | Pre-clinical | 26 |
| Vyndamax (tafamidis 61mg) | Pfizer | Pre-clinical | 30 |